Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trials In Progress
459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC